Gregory Lawrence Branigan

Mr. Gregory Lawrence Branigan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2022 in Cancer Medicine
Verified
Journal Article
Open access
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
GTGeorgina Torrandell‐Haro
Georgina Torrandell‐Haro
MSMaira Soto
Maira Soto
EGEdward P. Gelmann
Edward P. Gelmann
FVFrancesca Vitali
Francesca Vitali
RBRoberta Diaz Brinton
Roberta Diaz Brinton
Background: Prostate cancer and multiple neurodegenerative diseases (NDD) share an age‐associated pattern of onset. Therapy of prostate cancer is known to impact cognitive function. The objective of this study was to determine the impact of multiple classes of androgen‐targeting therapeutics (ATT) on the risk of NDD.Methods: A retrospective cohort study of men aged 45 and older with prostate within the US‐based Mariner claims data set between January 1 and 27, 2021. A propensity score approach was used to minimize measured and unmeasured selection bias. Disease risk was determined using Kaplan–Meier survival analyses.Results: Of the 1,798,648 men with prostate cancer, 209,722 met inclusion criteria. Mean (SD) follow‐up was 6.4 (1.8) years. In the propensity score‐matched population, exposure to ATT was associated with a minimal increase in NDD incidence (relative risk [RR], 1.07; 95% CI, 1.05–1.10; p < 0.001). However, GnRH agonists alone were associated with significantly increased NDD risk (RR, 1.47; 95% CI, 1.30–1.66; p <0.001). Abiraterone, commonly administered with GnRH agonists and low‐dose prednisone, was associated with a significantly decreased risk (RR, 0.77; 95% CI, 0.68–0.87; p < 0.001) of any NDD.Conclusions: Among patients with prostate cancer, GnRH agonist exposure was associated with an increased NDD risk. Abiraterone acetate reduced the risks of Alzheimer's disease and Parkinson's disease conferred by GnRH agonists, whereas the risk for ALS was reduced by androgen receptor inhibitors. Outcomes of these analyses contribute to addressing controversies in the field and indicate that GnRH agonism may be a predictable instigator of risk for NDD with opportunities for risk mitigation in combination with another ATT.

Verified
Journal Article
Open access
PDF file
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
KOKelly Shea Olsen
Kelly Shea Olsen
BBBella Burda
Bella Burda
MHMatthew Haemmerle
Matthew Haemmerle
JHJason Ho
Jason Ho
ADAngela Joan DiBenedetto
Angela Joan DiBenedetto
Brd2 belongs to the BET family of epigenetic transcriptional co-regulators that act as adaptor-scaffolds for the assembly of chromatin-modifying complexes and other factors at target gene promoters. Brd2 is a protooncogene and candidate gene for juvenile myoclonic epilepsy in humans, a homeobox gene regulator in Drosophila, and a maternal-zygotic factor and cell death modulator that is necessary for normal development of the vertebrate central nervous system (CNS). As two copies of Brd2 exist in zebrafish, we use antisense morpholino knockdown to probe the role of paralog Brd2b, as a comparative study to Brd2a, the ortholog of human Brd2. A deficiency in either paralog results in excess cell death and dysmorphology of the CNS, whereas only Brd2b deficiency leads to loss of circulation and occlusion of the pronephric duct. Co-knockdown of both paralogs suppresses single morphant defects, while co-injection of morpholinos with paralogous RNA enhances them, suggesting novel genetic interaction with functional antagonism. Brd2 diversification includes paralog-specific RNA variants, a distinct localization of maternal factors, and shared and unique spatiotemporal expression, providing unique insight into the evolution and potential functions of this gene.

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
GTGeorgina Torrandell‐Haro
Georgina Torrandell‐Haro
RBRoberta Diaz Brinton
Roberta Diaz Brinton

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
GTGeorgina Torrandell‐Haro
Georgina Torrandell‐Haro
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
FVFrancesca Vitali
Francesca Vitali
RBRoberta Diaz Brinton
Roberta Diaz Brinton

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
MSMaira Soto
Maira Soto
LNLeigh Neumayer
Leigh Neumayer
KRKathleen E Rodgers
Kathleen E Rodgers
RBRoberta Diaz Brinton
Roberta Diaz Brinton

31 December 2021 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
GBGregory Lawrence Branigan
Gregory Lawrence Branigan
GTGeorgina Torrandell‐Haro
Georgina Torrandell‐Haro
RBRoberta Diaz Brinton
Roberta Diaz Brinton